https://www.gov.uk/cma-cases/pharmaceutical-sector-anti-competitive-conduct
Liothyronine tablets: suspected excessive and unfair pricing - GOV.UK
The CMA investigated alleged excessive and unfair pricing with respect to liothyronine tablets under Chapter II CA98.
liothyroninetabletssuspectedexcessiveunfair